KR890011572A - 정신 기능을 증진시키는 방법 - Google Patents
정신 기능을 증진시키는 방법 Download PDFInfo
- Publication number
- KR890011572A KR890011572A KR1019890000761A KR890000761A KR890011572A KR 890011572 A KR890011572 A KR 890011572A KR 1019890000761 A KR1019890000761 A KR 1019890000761A KR 890000761 A KR890000761 A KR 890000761A KR 890011572 A KR890011572 A KR 890011572A
- Authority
- KR
- South Korea
- Prior art keywords
- hormone
- amount
- mental function
- dementia
- growth hormone
- Prior art date
Links
- 230000003340 mental effect Effects 0.000 title claims abstract 7
- 239000005556 hormone Substances 0.000 claims abstract 7
- 229940088597 hormone Drugs 0.000 claims abstract 7
- 230000006870 function Effects 0.000 claims abstract 6
- 230000002267 hypothalamic effect Effects 0.000 claims abstract 2
- 102000018997 Growth Hormone Human genes 0.000 claims description 5
- 108010051696 Growth Hormone Proteins 0.000 claims description 5
- 239000000122 growth hormone Substances 0.000 claims description 5
- 102000005157 Somatostatin Human genes 0.000 claims description 4
- 108010056088 Somatostatin Proteins 0.000 claims description 4
- 230000004044 response Effects 0.000 claims description 4
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical group C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 4
- 229960000553 somatostatin Drugs 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 15
- 206010012289 Dementia Diseases 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 4
- 102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 claims 3
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 claims 3
- 101710142969 Somatoliberin Proteins 0.000 claims 3
- 239000000960 hypophysis hormone Substances 0.000 claims 2
- 230000003557 neuropsychological effect Effects 0.000 claims 2
- 230000000975 bioactive effect Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 210000003016 hypothalamus Anatomy 0.000 claims 1
- 230000015654 memory Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000012544 monitoring process Methods 0.000 claims 1
- 230000006403 short-term memory Effects 0.000 claims 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Surgery (AREA)
- Neurology (AREA)
- Medical Informatics (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Optics & Photonics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 미로 패러다임에 있어서 소마토스타틴(성장호르몬 방출 억제인자)과 성장호르몬 방출인자로 처리한 쥐의 행동 양상을 컴퓨터로 기록한 도면.
제2도는 미로 패러다임에 있어서 운동활동과 학습에 미치는 소마토스타틴과 성장호르몬 방출인자의 영향을 나타낸 도면.
제3도는 연로한 대상자와(●) 알츠하이머형 노인성 치매가 조기발병(■)된 환자 및 만기발병(▲)된 환자에 있어서의 GRF유동 GH반응을 나타낸 도면.
Claims (16)
- 개체에게 정신기능을 증진시키는데 유효한 양으로 시상 하부의 뇌하수체 호르몬을 투여하는 것을 특징으로 하는 개체의 정신기능을 증진시키는 방법.
- 제1항에 있어서, 호르몬이 소마토스타틴, 성장호르몬 방출인자, 그의 생리활성적인 단편, 또는 이들의 혼합물인 것이 특징인 개체의 정신기능을 증진시키는 방법.
- 제2항에 있어서, 호르몬을 약1 내지 약 10㎍/kg의 양으로 정맥에 투여함을 특징으로 하는 개체의 정신기능을 증진시키는 방법.
- 제2항에 있어서, 호르몬을 약5 내지 약 50㎍/kg의 양으로 피하에 투여함을 특징으로 하는 개체의 정신기능을 증진시키는 방법.
- 제2항에 있어서, 개체가 치매증세를 가지며 그 유효량이 치매정도를 저하시키는데 충분한 양인 것이 특징인 개체의 정신기능을 증진시키는 방법.
- 제5항에 있어서, 치매가 알츠하이머형 노인성 치매인 것이 특징인 개체의 정신기능을 증진시키는 방법.
- 제2항에 있어서, 정신기능이 기억력이고 그 유효량이 단기간 기억력을 개선시키는데 충분한 양인것이 특징인 개체의 정신기능을 증진시키는 방법.
- 제2항에 있어서, 정신기능이 주목도 범위이고 그 유효량이 주목도 범위를 증가시키는데 충분한 양인 것이 특징인 개체의 정신기능을 증진시키는 방법.
- 제2항에 있어서, 상기 투여에 대한 신경정신적 반응과 성장호르몬 반응중 적어도 한가지를 모니터함을 특징으로 하는 개체의 정신기능을 증진시키는 방법.
- 제2항에 있어서, 상기 호르몬이 소마토스타틴 또는 그의 활성 단편인 것이 특징인 개체의 정신기능을 증진시키는 방법.
- 제2항에 있어서, 상기 호르몬이 성장호르몬 방출인자나 또는 그의 활성단편인 것이 특징인 개체의 정신기능을 증진시키는 방법.
- 개체에게 정상적인 개체의 정신기능을 증진시키는데 유효한 양으로 시상하부의 뇌하수체 호르몬을 투여하고 상기 부여에 대한 신경정신적 반응 및 성장호르몬 반응을 모니터하는 것을 특징으로 하는 개체에 있어서의 알츠하이머형 노인성 치매를 검색하는 방법.
- 제12항에 있어서, 투여량이 약 1내지 50㎍/kg인 것이 특징인 개체에 있어서의 알츠하이머형 노인성 치매를 검색하는 방법.
- 제13항에 있어서, 호르몬이 성장호르몬 방출인자나 또는 그의 활성단편인 것이 특징인 개체에 있어서의 알츠하이머형 노인성 치매를 검색하는 방법.
- 제14항에 있어서, 투여를 약 1내지 10㎍/kg의 양으로 정맥에 투여하는 것이 특징인 개체에 있어서의 알츠하이머형 노인성 치매를 겸색하는 방법.
- 제14항에 있어서, 투여를 약 5내지 50㎍/kg의 양으로 피하에 투여하는 것이 특징인 개체에 있어서의 알츠하이머형 노인성 치매를 검색하는 방법.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/148,667 US4939124A (en) | 1988-01-26 | 1988-01-26 | Treatment and diagnosis of dementia |
| ES148667 | 1988-01-26 | ||
| US07/206,100 US5089472A (en) | 1988-01-26 | 1988-06-13 | Use of growth hormone releasing factor for improving mental function |
| ES206100 | 1988-06-13 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR890011572A true KR890011572A (ko) | 1989-08-21 |
| KR970002484B1 KR970002484B1 (en) | 1997-03-05 |
Family
ID=26846051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR89000761A KR970002484B1 (en) | 1988-01-26 | 1989-01-25 | Method of enhancing mental function |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US5089472A (ko) |
| EP (1) | EP0326381B1 (ko) |
| JP (2) | JP2847098B2 (ko) |
| KR (1) | KR970002484B1 (ko) |
| CN (1) | CN1055641C (ko) |
| AT (1) | ATE106745T1 (ko) |
| AU (1) | AU615714B2 (ko) |
| CA (1) | CA1341017C (ko) |
| DE (1) | DE68915793T2 (ko) |
| DK (1) | DK174866B1 (ko) |
| FI (1) | FI890389A (ko) |
| IL (1) | IL89056A (ko) |
| NO (1) | NO890336L (ko) |
| RU (1) | RU2024261C1 (ko) |
| UA (1) | UA19804A (ko) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994022469A1 (en) * | 1993-04-02 | 1994-10-13 | Ohio University | Enhancement of learning and/or memory by a human somatotropin |
| CA2699078A1 (en) * | 2007-09-11 | 2009-04-09 | Dorian Bevec | Use of grf-1 (1-29 ) and corticotropin-releasing factor as therapeutic agents |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8318552D0 (en) * | 1983-07-08 | 1983-08-10 | Sandoz Ltd | Organic compounds |
| US4747825A (en) * | 1984-06-29 | 1988-05-31 | Ferring Laboratories, Inc. | Apparatus and methodology for pulsed administration of growth promoting agents |
| JPH085913B2 (ja) * | 1985-09-12 | 1996-01-24 | ザ・アドミニストレ−タ−ズ・オブ・ザ・ツ−レイン・エデユケイシヨナル・フアンド | 治療用ソマトスタチン同族体 |
| US4939124A (en) * | 1988-01-26 | 1990-07-03 | Laboratorios Serono S.A. | Treatment and diagnosis of dementia |
-
1988
- 1988-06-13 US US07/206,100 patent/US5089472A/en not_active Expired - Lifetime
-
1989
- 1989-01-23 AU AU28700/89A patent/AU615714B2/en not_active Expired
- 1989-01-24 IL IL8905689A patent/IL89056A/en unknown
- 1989-01-25 KR KR89000761A patent/KR970002484B1/ko not_active IP Right Cessation
- 1989-01-25 JP JP1017386A patent/JP2847098B2/ja not_active Expired - Lifetime
- 1989-01-25 RU SU894613597A patent/RU2024261C1/ru active
- 1989-01-25 UA UA4613597A patent/UA19804A/uk unknown
- 1989-01-25 DK DK198900314A patent/DK174866B1/da not_active IP Right Cessation
- 1989-01-26 EP EP89300751A patent/EP0326381B1/en not_active Expired - Lifetime
- 1989-01-26 FI FI890389A patent/FI890389A/fi not_active Application Discontinuation
- 1989-01-26 CN CN89101534A patent/CN1055641C/zh not_active Expired - Lifetime
- 1989-01-26 AT AT89300751T patent/ATE106745T1/de not_active IP Right Cessation
- 1989-01-26 CA CA000589280A patent/CA1341017C/en not_active Expired - Fee Related
- 1989-01-26 NO NO89890336A patent/NO890336L/no unknown
- 1989-01-26 DE DE68915793T patent/DE68915793T2/de not_active Expired - Lifetime
-
1998
- 1998-02-16 JP JP10032715A patent/JP2965949B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2847098B2 (ja) | 1999-01-13 |
| JPH10251167A (ja) | 1998-09-22 |
| CN1055641C (zh) | 2000-08-23 |
| JP2965949B2 (ja) | 1999-10-18 |
| EP0326381A3 (en) | 1991-08-14 |
| NO890336D0 (no) | 1989-01-26 |
| IL89056A (en) | 1994-07-31 |
| NO890336L (no) | 1989-07-27 |
| DK31489A (da) | 1989-07-27 |
| DE68915793D1 (de) | 1994-07-14 |
| RU2024261C1 (ru) | 1994-12-15 |
| AU615714B2 (en) | 1991-10-10 |
| UA19804A (uk) | 1997-12-25 |
| KR970002484B1 (en) | 1997-03-05 |
| JPH0242025A (ja) | 1990-02-13 |
| DK31489D0 (da) | 1989-01-25 |
| DE68915793T2 (de) | 1995-03-09 |
| EP0326381B1 (en) | 1994-06-08 |
| ATE106745T1 (de) | 1994-06-15 |
| FI890389A0 (fi) | 1989-01-26 |
| EP0326381A2 (en) | 1989-08-02 |
| DK174866B1 (da) | 2004-01-05 |
| CA1341017C (en) | 2000-06-06 |
| AU2870089A (en) | 1989-07-27 |
| CN1036509A (zh) | 1989-10-25 |
| US5089472A (en) | 1992-02-18 |
| IL89056A0 (en) | 1989-08-15 |
| FI890389A (fi) | 1989-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sandman et al. | Behavioral inhibition as modified by melanocyte-stimulating hormone (MSH) and light-dark conditions | |
| KR930702022A (ko) | 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법 | |
| KR950701816A (ko) | 말초 신경병의 예방 및 치료(prevention and treatment of peripheral neuropathy) | |
| ES2137948T3 (es) | Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina. | |
| RU2000100346A (ru) | Способы лечения ожирения | |
| DE3889536T2 (de) | Behandlung von krebs mit somatostatin und mit analogen davon. | |
| DE68916387T2 (de) | Verwendung von Nalmefen oder Naltrexon bei der Behandlung von Autoimmunerkrankungen. | |
| ES2181676T3 (es) | Diagnosis y tratamiento de enfermedades autoinmunitarias. | |
| KR950703353A (ko) | 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus) | |
| Yehuda et al. | Thermoregulatory and locomotor effects of DSIP: paradoxical interaction with d-amphetamine | |
| KR920700227A (ko) | 초고활성 인체 인슐린 동족체 | |
| DE69031563D1 (de) | Behandlung der autoimmunen uveoretinitis in menschen | |
| KR890011572A (ko) | 정신 기능을 증진시키는 방법 | |
| ATE184484T1 (de) | Wirkstoffe zur behandlung von suchterkrankungen | |
| KR960705578A (ko) | 경증 질환을 가진 b형 간염 보균자의 치료방법(method for treating hepatitis b carriers with minimal disease) | |
| Dougherty et al. | Differential modification of morphine and methadone dependence by interferon alpha | |
| Singer et al. | Does basal cholinergic activity potentiate exogenous secretin for stimulation of pancreatic bicarbonate output in dogs? | |
| DE68910010D1 (de) | Verwendung von Dapiprazol zur Herstellung eines Arzneimittels zur Verhinderung des Toleranzentwicklung bei der analgetischen Behandlung mit Morphin. | |
| Frostad | Astemizole in the treatment of seasonal allergic rhinitis: A double-blind comparison with clemastine in patients sensitive to tree and grass pollen: Special reference to side effects registered in psychological tests. | |
| DE69618511D1 (de) | Gammainterferon enthaltende Zusammensetzung zur Prurigo-Behandlung | |
| Di Giannuario et al. | ß-endorphin cleavage products devoid of opioid properties exert anticonvulsive EEG effect in the rabbit | |
| McManus | Effects of chronic antidepressant drug administration on gabaergic mechanisms in rat brain | |
| Clark et al. | Persistent sleep abnormalities in primary alcoholics with secondary depression | |
| Mazur | Effects of caffeine and ethanol on the level of these agents in rat blood serum. | |
| KR930700109A (ko) | 신경 질환 치료용 4,4'-[9h-플루오렌-9-일리덴비스(메틸렌)]-비스피리미딘 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| N231 | Notification of change of applicant | ||
| E902 | Notification of reason for refusal | ||
| G160 | Decision to publish patent application | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20080808 Year of fee payment: 12 |
|
| LAPS | Lapse due to unpaid annual fee |